|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI
|
|
2
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar
|
|
3
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pei Y, Yao Q, Li Y, Zhang X and Xie B:
microRNA-211 regulates cell proliferation, apoptosis and
migration/invasion in human osteosarcoma via targeting EZRIN. Cell
Mol Biol Lett. 24:482019. View Article : Google Scholar
|
|
5
|
Shen JK, Cote GM, Choy E, Yang P, Harmon
D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, et al:
Programmed cell death ligand 1 expression in osteosarcoma. Cancer
Immunol Res. 2:690–698. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tawbi HA, Burgess M, Bolejack V, Van Tine
BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA,
et al: Pembrolizumab in advanced soft-tissue sarcoma and bone
sarcoma (SARC028): A multicentre, two-cohort, single-arm,
open-label, phase 2 trial. Lancet Oncol. 18:1493–1501. 2017.
View Article : Google Scholar
|
|
7
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Daud AI, Wolchok JD, Robert C, Hwu WJ,
Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al:
Programmed death-ligand 1 expression and response to the
anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin
Oncol. 34:4102–4109. 2016. View Article : Google Scholar
|
|
9
|
Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao
N, Sun B and Wang G: Ferroptosis: Past, present and future. Cell
Death Dis. 11:882020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He GN, Bao NR, Wang S, Xi M, Zhang TH and
Chen FS: Ketamine induces ferroptosis of liver cancer cells by
targeting lncRNA PVT1/miR-214-3p/GPX4. Drug Des Devel Ther.
15:3965–3978. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al:
CD8+ T cells regulate tumour ferroptosis during cancer
immunotherapy. Nature. 569:270–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Bahrami A, Pappo A, Easton J,
Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al:
Recurrent somatic structural variations contribute to tumorigenesis
in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen W, Liao Y, Sun P, Tu J, Zou Y, Fang
J, Chen Z, Li H, Chen J, Peng Y, et al: Construction of an ER
stress-related prognostic signature for predicting prognosis and
screening the effective anti-tumor drug in osteosarcoma. J Transl
Med. 22:662024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pradervand S, Weber J, Thomas J, Bueno M,
Wirapati P, Lefort K, Dotto GP and Harshman K: Impact of
normalization on miRNA microarray expression profiling. RNA.
15:493–501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nguyen CB, Kumar S, Zucknick M, Kristensen
VN, Gjerstad J, Nilsen H and Wyller VB: Associations between
clinical symptoms, plasma norepinephrine and deregulated immune
gene networks in subgroups of adolescent with chronic fatigue
syndrome. Brain Behav Immun. 76:82–96. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang T, Wang S, Hua D, Shi X, Deng H, Jin
S and Lv X: Identification of ZIP8-induced ferroptosis as a major
type of cell death in monocytes under sepsis conditions. Redox
Biol. 69:1029852024. View Article : Google Scholar
|
|
17
|
Yu D, Hu H, Zhang Q, Wang C, Xu M, Xu H,
Geng X, Cai M, Zhang H, Guo M, et al: Acevaltrate as a novel
ferroptosis inducer with dual targets of PCBP1/2 and GPX4 in
colorectal cancer. Signal Transduct Target Ther. 10:2112025.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zou Y, Palte MJ, Deik AA, Li H, Eaton JK,
Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, et al: A
GPX4-dependent cancer cell state underlies the clear-cell
morphology and confers sensitivity to ferroptosis. Nat Commun.
10:16172019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gentles AJ, Newman AM, Liu CL, Bratman SV,
Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The
prognostic landscape of genes and infiltrating immune cells across
human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bashur L and Zhou G: Cancer stem cells in
osteosarcoma. Case Orthop J. 10:38–42. 2013.PubMed/NCBI
|
|
23
|
Wang SD, Li HY, Li BH, Xie T, Zhu T, Sun
LL, Ren HY and Ye ZM: The role of CTLA-4 and PD-1 in anti-tumor
immune response and their potential efficacy against osteosarcoma.
Int Immunopharmacol. 38:81–89. 2016. View Article : Google Scholar
|
|
24
|
Tsukahara T, Emori M, Murata K, Mizushima
E, Shibayama Y, Kubo T, Kanaseki T, Hirohashi Y, Yamashita T, Sato
N and Torigoe T: The future of immunotherapy for sarcoma. Expert
Opin Biol Ther. 16:1049–1057. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scott MC, Temiz NA, Sarver AE, LaRue RS,
Rathe SK, Varshney J, Wolf NK, Moriarity BS, O'Brien TD, Spector
LG, et al: Comparative transcriptome analysis quantifies immune
cell transcript levels, metastatic progression, and survival in
osteosarcoma. Cancer Res. 78:326–337. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Merchant MS, Melchionda F, Sinha M, Khanna
C, Helman L and Mackall CL: Immune reconstitution prevents
metastatic recurrence of murine osteosarcoma. Cancer Immunol
Immunother. 56:1037–1046. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morgan PK, Pernes G, Huynh K, Giles C,
Paul S, Smith AAT, Mellett NA, Liang A, van Buuren-Milne T, Veiga
CB, et al: A lipid atlas of human and mouse immune cells provides
insights into ferroptosis susceptibility. Nat Cell Biol.
26:645–659. 2024. View Article : Google Scholar
|
|
28
|
Ma L, Chen C, Zhao C, Li T, Ma L, Jiang J,
Duan Z, Si Q, Chuang TH, Xiang R and Luo Y: Targeting carnitine
palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes
with immunotherapy in lung cancer. Signal Transduct Target Ther.
9:642024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bell HN, Stockwell BR and Zou W: Ironing
out the role of ferroptosis in immunity. Immunity. 57:941–956.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng Y, Sun L, Guo J and Ma J: The
crosstalk between ferroptosis and anti-tumor immunity in the tumor
microenvironment: Molecular mechanisms and therapeutic controversy.
Cancer Commun (Lond). 43:1071–1096. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Li Y, Tuerxun H and Zhao Y, Liu X
and Zhao Y: Firing up ‘cold’ tumors: Ferroptosis causes immune
activation by improving T cell infiltration. Biomed Pharmacother.
179:1172982024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng Z, Wang K, Wang Y, Liu T, Li J, Wang
Y, Chen W, Awuti R, Zhou H, Tong W, et al: Ferroptosis mediated by
the IDO1/Kyn/AhR pathway triggers acute thymic involution in
sepsis. Cell Death Dis. 16:5622025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou J, Yin H, Pan J, Yin R, Wei X, Shen
M, Cai L, Liu Z, Zhao J, Chen W, et al: Lnk deficiency attenuates
the immunosuppressive capacity of MDSCs via ferroptosis to suppress
tumor development. Cell Death Dis. 16:6102025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li S, Ouyang X, Sun H, Jin J, Chen Y, Li
L, Wang Q, He Y, Wang J, Chen T, et al: DEPDC5 protects
CD8+ T cells from ferroptosis by limiting
mTORC1-mediated purine catabolism. Cell Discov. 10:532024.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu J, Cui L, Hou B, Ding X, Liu H, Sun W,
Mi Y, Chen Y and Zou Z: Ferroptosis in tumor associated immune
cells: A double-edged sword against tumors. Crit Rev Oncol Hematol.
212:1048182025. View Article : Google Scholar
|
|
36
|
Gupta T, Wu SR, Chang LC, Lin FC, Shan YS,
Yeh CS and Su WP: Radiocleavable rare-earth nanoactivators
targeting over-expressed folate receptors induce mitochondrial
dysfunction and remodel immune suppressive microenvironment in
pancreatic cancer. J Nanobiotechnology. 23:5622025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li P, Huang C, He Y, Lei X, Shen X, Xu J,
Mo Y, Sun X, Zheng L and Niu Y: M2 macrophage-laden vascular grafts
orchestrate the optimization of the inflammatory microenvironment
for abdominal aorta regeneration. Acta Biomater. 204:323–339. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu K, Zhu X, Sun S, Yang W, Liu S, Tang
Z, Zhang R, Li J, Shen T and Hei M: Inhibition of TLR4 prevents
hippocampal hypoxic-ischemic injury by regulating ferroptosis in
neonatal rats. Exp Neurol. 345:1138282021. View Article : Google Scholar
|
|
39
|
Flores RJ, Kelly AJ, Li Y, Nakka M,
Barkauskas DA, Krailo M, Wang LL, Perlaky L, Lau CC, Hicks MJ and
Man TK: A novel prognostic model for osteosarcoma using circulating
CXCL10 and FLT3LG. Cancer. 123:144–154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Castro F, Cardoso AP, Gonçalves RM, Serre
K and Oliveira MJ: Interferon-gamma at the crossroads of tumor
immune surveillance or evasion. Front Immunol. 9:8472018.
View Article : Google Scholar
|
|
41
|
Shtrichman R and Samuel CE: The role of
gamma interferon in antimicrobial immunity. Curr Opin Microbiol.
4:251–259. 2001. View Article : Google Scholar
|
|
42
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 expression. Cell Rep. 19:1189–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rosadini CV, Zanoni I, Odendall C, Green
ER, Paczosa MK, Philip NH, Brodsky IE, Mecsas J and Kagan JC: A
single bacterial immune evasion strategy dismantles both MyD88 and
TRIF signaling pathways downstream of TLR4. Cell Host Microbe.
18:682–693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bauer AK, Dixon D, DeGraff LM, Cho HY,
Walker CR, Malkinson AM and Kleeberger SR: Toll-like receptor 4 in
butylated hydroxytoluene-induced mouse pulmonary inflammation and
tumorigenesis. J Natl Cancer Inst. 97:1778–1781. 2005. View Article : Google Scholar
|
|
45
|
Li L, Ouyang Y, Wang W, Hou D and Zhu Y:
The landscape and prognostic value of tumor-infiltrating immune
cells in gastric cancer. PeerJ. 7:e79932019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gu-Trantien C, Loi S, Garaud S, Equeter C,
Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C,
Manfouo-Foutsop G, et al: CD4+ follicular helper T cell
infiltration predicts breast cancer survival. J Clin Invest.
123:2873–2892. 2013. View Article : Google Scholar
|
|
47
|
Gambardella V, Castillo J, Tarazona N,
Gimeno-Valiente F, Martínez-Ciarpaglini C, Cabeza-Segura M, Roselló
S, Roda D, Huerta M, Cervantes A and Fleitas T: The role of
tumor-associated macrophages in gastric cancer development and
their potential as a therapeutic target. Cancer Treat Rev.
86:1020152020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Harrington BK, Wheeler E, Hornbuckle K,
Shana'ah AY, Youssef Y, Smith L, Hassan Q II, Klamer B, Zhang X,
Long M, et al: Modulation of immune checkpoint molecule expression
in mantle cell lymphoma. Leuk Lymphoma. 60:2498–2507. 2019.
View Article : Google Scholar
|
|
49
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Motzer RJ, Rini BI, McDermott DF, Redman
BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S,
Logan TF, et al: Nivolumab for metastatic renal cell carcinoma:
Results of a randomized phase II trial. J Clin Oncol. 33:1430–1437.
2015. View Article : Google Scholar
|
|
51
|
Goralski KB, Jackson AE, McKeown BT and
Sinal CJ: More than an adipokine: The complex roles of chemerin
signaling in cancer. Int J Mol Sci. 20:47782019. View Article : Google Scholar
|
|
52
|
Tran TH, Tran TTP, Truong DH, Nguyen HT,
Pham TT, Yong CS and Kim JO: Toll-like receptor-targeted particles:
A paradigm to manipulate the tumor microenvironment for cancer
immunotherapy. Acta Biomater. 94:82–96. 2019. View Article : Google Scholar : PubMed/NCBI
|
